Skip to main content

Table 3 Outcome measures for the treatment of patients included in the study on thiamin treatment and Plasmodium falciparum malaria in Laos†

From: Thiamin supplementation does not reduce the frequency of adverse events after anti-malarial therapy among patients with falciparum malaria in southern Laos

Variables

Treatment groups

 

All (N = 630)

Thiamin (n = 314)

Placebo (n = 316)

P. falciparum recurrence, no. (%)a

50 (8)

20 (6)

30 (9)

42-day cure rate, no. (%) of patientsa

612/630 (97)

308/314 (98)

304/316 (96)

42-day cure rate per protocol, no. (%) of patientsΨ

599/617 (97)

303/309 (98)

296/308 (96)

Fever clearance time, mean hours (95%CI)a,b

26.5 (25.1 – 27.9)

26.6 (24.7 – 28.6)

26.4 (24.4 – 28.4)

Patients remained febrile at day 1, no. (%)

317 (50)

157 (50)

160 (51)

Patients remained febrile at day 2, no. (%)

86 (14)

44 (14)

42 (13)

Parasite clearance time, median days (range)a,c

1 (1–3)

1 (1–3)

1 (1–3)

Positive parasitaemia at day 1, no. (%) of patients

191/627 (30)

98/311 (31.5)

93/316 (29)

Positive parasitaemia at day 2, no. (%) of patients

1

0

1

Gametocytaemia detected at anytime, no. (%) of patients

31 (5)

15 (5)

16 (5)

Gametocytaemia after treatment, no. (%) of patients

4 (0.6)

1 (0.3)

3 (1)

Gametocyte clearance time, median days (range)d

7 (1 – 21)

7 (1–14)

7 (7 – 21)

Gametocyte cleared by day 7, no. (%)d

28 (90)

14 (93)

14 (87.5)

Median (range) gametocyte-person-weeksd

0.42 (0.14 – 1.0)

0.42 (0.14 – 1.0)

0.42 (0.14 – 0.42)

P. vivax appearance after treatment for P. falciparum, no. (%) of patients

21/630 (3)

8/314 (2.5)

13/316 (4)

Day 0 haematocrit, mean % (95%CI)

35.6 (35.0 – 36.1)

35.6 (34.8 – 36.4)

35.5 (34.7 – 36.3)

Day 1 haematocrit, mean % (95%CI)

32.0 (31.5 – 32.5)

32.1 (31.4 – 32.8)

31.9 (31.1 – 32.6)

Day 2 haematocrit, mean % (95%CI)

30.7 (30.2 – 31.2)

30.9 (30.2 – 31.6)

30.6 (29.9 – 31.3)

Day 3 haematocrit, mean % (95%CI)

30.7 (30.2 – 31.2)

30.9 (30.2 – 31.6)

30.6 (29.9 – 31.3)

Day 7 haematocrit, mean % (95%CI)

32.9 (32.5 – 33.3)

33.1 (32.5 – 33.7)

32.7 (32.1 – 33.3)

Day 14 haematocrit, mean % (95%CI)

34.0 (33.7 – 34.4)

34.1 (33.6 – 34.7)

33.9 (33.4 – 34.5)

Day 21 haematocrit, mean % (95%CI)

35.4 (35.0 – 35.0)

35.4 (34.9 – 35.9)

35.3 (34.8 – 35.8)

Day 28 haematocrit, mean % (95%CI)

35.9 (35.6 – 36.3)

36.0 (35.5 – 36.5)

35.8 (35.4 – 36.3)

Day 35 haematocrit, mean % (95%CI)

36.3 (36.0 – 36.7)

36.3 (35.8 – 36.8)

36.3 (35.8 – 36.8)

Day 42 haematocrit, mean % (95%CI)

37.5 (37.1 – 37.8)

37.5 (37.0 – 38.0)

37.5 (37.0 – 38.0)

  1. NOTE. †No statistical difference was found between thiamin and placebo groups.
  2. ΨThe patient with undetermined PCR result was classified as recrudescent infection.
  3. aIntention-to-treat analysis.
  4. bData were available from 295 and 306 patients in thiamin and placebo groups, respectively.
  5. cData were available from 311 and 316 patients in thiamin and placebo groups, respectively.
  6. dData were available from 15 and 16 patients in thiamin and placebo groups, respectively.